IL239211B - Anti-a–ntb antibodies and related compositions and methods - Google Patents

Anti-a–ntb antibodies and related compositions and methods

Info

Publication number
IL239211B
IL239211B IL239211A IL23921115A IL239211B IL 239211 B IL239211 B IL 239211B IL 239211 A IL239211 A IL 239211A IL 23921115 A IL23921115 A IL 23921115A IL 239211 B IL239211 B IL 239211B
Authority
IL
Israel
Prior art keywords
ntb
antibodies
methods
related compositions
compositions
Prior art date
Application number
IL239211A
Other languages
English (en)
Hebrew (he)
Other versions
IL239211A0 (en
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of IL239211A0 publication Critical patent/IL239211A0/en
Publication of IL239211B publication Critical patent/IL239211B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL239211A 2012-12-21 2015-06-04 Anti-a–ntb antibodies and related compositions and methods IL239211B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
IL239211A0 IL239211A0 (en) 2015-07-30
IL239211B true IL239211B (en) 2020-08-31

Family

ID=50979291

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239211A IL239211B (en) 2012-12-21 2015-06-04 Anti-a–ntb antibodies and related compositions and methods
IL271305A IL271305B (en) 2012-12-21 2019-12-10 Anti-ntb–a antibodies and related compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL271305A IL271305B (en) 2012-12-21 2019-12-10 Anti-ntb–a antibodies and related compositions and methods

Country Status (10)

Country Link
US (4) US9708404B2 (2)
EP (1) EP2934585B1 (2)
JP (4) JP6449777B2 (2)
CN (2) CN105188749B (2)
AU (1) AU2013364043B2 (2)
CA (1) CA2893977C (2)
EA (1) EA031025B1 (2)
HK (1) HK1216850A1 (2)
IL (2) IL239211B (2)
WO (1) WO2014100740A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700141T3 (es) * 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
CN105188749B (zh) * 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
KR20170058960A (ko) * 2014-09-09 2017-05-29 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 Agr2 및 그의 수용체 c4.4a 에 대한 차단 모노클로날 항체
JP6214790B2 (ja) * 2014-09-16 2017-10-18 イース チャーム リミテッド 抗ｅｇｆｒ抗体および同抗体の使用法
EP3200822B1 (en) * 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to l1cam (cd171)
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SG10202005460RA (en) * 2015-06-30 2020-07-29 Seattle Genetics Inc Anti-ntb-a antibodies and related compositions and methods
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
AU2019221544B2 (en) * 2018-02-13 2025-07-10 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
AU2020298833A1 (en) 2019-07-03 2022-01-20 Oxford Biotherapeutics Ltd Antibodies and methods of use
EP4017542A1 (en) * 2019-10-04 2022-06-29 Tae Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
US20230092356A1 (en) 2019-12-06 2023-03-23 Thoas Fioretos Novel agents and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
AU5752696A (en) * 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
WO2001055336A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to cd84-like polypeptides and polynucleotides
AU2001253362A1 (en) 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
JP4451059B2 (ja) 2000-09-01 2010-04-14 ジェネンテック インコーポレイテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
JP2004533222A (ja) 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
US7138243B2 (en) 2001-07-19 2006-11-21 Innate Pharma, S.A. NTB-A, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
CA2476555A1 (en) 2002-02-14 2003-08-21 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2500521A1 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
US8375932B2 (en) * 2007-10-03 2013-02-19 Germans Boada, S.A. Manual ceramics cutter
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
RU2011111640A (ru) 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
CN102333859B (zh) * 2008-09-16 2015-04-22 三井化学株式会社 由来自植物的原料生产乳酸的方法及生产乳酸的细菌
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2443150B1 (en) 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
BR112012017696A2 (pt) 2010-01-18 2017-10-03 Novo Nordisk Healthcare Ag Purificação de fatores de coagulação de sangue
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2643350A4 (en) 2010-11-22 2015-01-07 Innate Pharma Sa TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN105188749B (zh) * 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
SG10202005460RA (en) * 2015-06-30 2020-07-29 Seattle Genetics Inc Anti-ntb-a antibodies and related compositions and methods

Also Published As

Publication number Publication date
CA2893977A1 (en) 2014-06-26
EP2934585B1 (en) 2018-06-13
EA031025B1 (ru) 2018-11-30
JP6817674B2 (ja) 2021-01-20
US20190375841A1 (en) 2019-12-12
WO2014100740A1 (en) 2014-06-26
CN107880126B (zh) 2021-03-30
IL271305A (en) 2020-01-30
AU2013364043A1 (en) 2015-06-18
US20170320944A1 (en) 2017-11-09
JP2019014752A (ja) 2019-01-31
CA2893977C (en) 2024-02-13
US20230105802A1 (en) 2023-04-06
HK1216850A1 (zh) 2016-12-09
EP2934585A1 (en) 2015-10-28
JP2022066565A (ja) 2022-04-28
US10435468B2 (en) 2019-10-08
US20150376276A1 (en) 2015-12-31
IL239211A0 (en) 2015-07-30
JP2020055870A (ja) 2020-04-09
JP2016503067A (ja) 2016-02-01
CN105188749A (zh) 2015-12-23
IL271305B (en) 2021-01-31
CN105188749B (zh) 2017-12-19
JP6449777B2 (ja) 2019-01-09
EA201591191A1 (ru) 2015-11-30
EP2934585A4 (en) 2016-07-13
US9708404B2 (en) 2017-07-18
AU2013364043B2 (en) 2018-01-04
CN107880126A (zh) 2018-04-06

Similar Documents

Publication Publication Date Title
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL272831B (en) Meditops and Meditop binding antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
ZA201502880B (en) Compositions and methods for immunotherapy
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL254416A0 (en) Anti-asic1 antibodies and their uses
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
IL234695A0 (en) Antigen compositions and methods
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
GB201208372D0 (en) Antibodies and uses thereof
GB201116340D0 (en) Compositions and methods
GB201209584D0 (en) Modified antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed